At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Ruben A. Mesa, MD, Chair of Hematology at Mayo Clinic, Arizona, TX, discusses the trial design and results of the phase 3 PERSIST-1 trial of pacritinib, versus best available therapy in patients with primary myelofibrosis, post-polycythemia vera myelofibrosis, or post-essential thrombocythemia-myelofibrosis.
Results of the phase 3 PERSIST-1 trial of pacritinib in myelofibrosis
26th June 2015
Hematology
Rate this content's potential impact on patient outcomes
Thank you!
Please share some more information on the rating you have given